You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest DPP-4 Inhibitor Articles
Popular DPP-4 Inhibitor Articles
Highly Recommended DPP-4 Inhibitor Articles
Send a link to this page to your friends and colleagues.
Eli Lilly and Company has begun US sales of Jentadueto, a drug for type 2 diabetes that combines Tradjenta and metformin. The drug, in tablet form, is taken twice daily and is available in three prescription strengths.
Tradjenta (linagliptin) is a DPP-4 inhibitor that regulates insulin levels. The drug was introduced less than a year ago to the US market.
Metformin, which regulates the liver's glucose production, is an older standby drug that physicians often prescribe as the first drug therapy for recently diagnosed type 2s.
Lilly developed Tradjenta in conjunction with German drug maker Boehringer Ingelheim.
0 comments - Mar 10, 2012
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.